Abstract
Recombinant adeno-associated viral vectors (rAAV) have now been used in several clinical trials to treat a variety of diseases, and are currently the preferred choice of many investigators in the field, due to both their low pathogenicity and immunogenicity compared with other viral vectors, as well as localized long-term gene expression, despite their limitations of DNA size packaging and speed of expression. Recently, a number of advances have led to new generations of rAAV vectors, with improved features. This review addresses the various strategies employed to such effect, namely exploring distinct serotype tropisms, the production of mosaic and chimeric capsids, the selection of vectors through directed evolution, the development of self-complementary vectors, the use of pharmacological adjuvants and the induction of specific capsid mutations. Such approaches are expected to help the establishment of rAAV-based clinical gene therapy in the near future.
Keywords: Viral vectors, adeno-associated virus, directed evolution, selective mutagenesis, gene transfer, safety, efficacy.
Current Gene Therapy
Title:Advances in Recombinant Adeno-Associated Viral Vectors for Gene Delivery
Volume: 13 Issue: 5
Author(s): Hilda Petrs-Silva and Rafael Linden
Affiliation:
Keywords: Viral vectors, adeno-associated virus, directed evolution, selective mutagenesis, gene transfer, safety, efficacy.
Abstract: Recombinant adeno-associated viral vectors (rAAV) have now been used in several clinical trials to treat a variety of diseases, and are currently the preferred choice of many investigators in the field, due to both their low pathogenicity and immunogenicity compared with other viral vectors, as well as localized long-term gene expression, despite their limitations of DNA size packaging and speed of expression. Recently, a number of advances have led to new generations of rAAV vectors, with improved features. This review addresses the various strategies employed to such effect, namely exploring distinct serotype tropisms, the production of mosaic and chimeric capsids, the selection of vectors through directed evolution, the development of self-complementary vectors, the use of pharmacological adjuvants and the induction of specific capsid mutations. Such approaches are expected to help the establishment of rAAV-based clinical gene therapy in the near future.
Export Options
About this article
Cite this article as:
Petrs-Silva Hilda and Linden Rafael, Advances in Recombinant Adeno-Associated Viral Vectors for Gene Delivery, Current Gene Therapy 2013; 13 (5) . https://dx.doi.org/10.2174/15665232113136660028
DOI https://dx.doi.org/10.2174/15665232113136660028 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Two Promising Anti-Cancer Compounds, 2-Hydroxycinnaldehyde and 2- Benzoyloxycinnamaldehyde: Where do we stand?
Combinatorial Chemistry & High Throughput Screening Radiolabeled Nanoparticles, Angionesis and Therapeutics of Cancer Researches Together With Preclinical Models
Current Radiopharmaceuticals Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Gene Therapy for Haemophagocytic Lymphohistiocytosis
Current Gene Therapy Substance Abuse, HIV-1 and Hepatitis
Current HIV Research Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of 2-Substituted Fendiline Analogues as Antileukemics
Letters in Drug Design & Discovery Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets SELDI Protein Chip Technology for the Detection of Serum Biomarkers for Liver Disease
Protein & Peptide Letters Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Induced Pluripotent Stem Cells (iPSCs) in the Modeling of Hepatitis C Virus Infection
Current Stem Cell Research & Therapy Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing
Current Gene Therapy Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy
Current Medicinal Chemistry Cell Dormancy and Tumor Refractory
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and Antiproliferative Activity of 2-Acetamidothiazole-5- carboxamide Derivatives
Medicinal Chemistry